News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,715 Results
Type
Article (39996)
Company Profile (249)
Press Release (664469)
Multimedia
Podcasts (58)
Webinars (14)
Section
Business (204273)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81131)
Employer Resources (172)
FDA (16245)
Job Trends (14886)
News (345486)
Policy (32604)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1437)
Antibody-drug conjugate (ADC) (151)
Approvals (16243)
Artificial intelligence (307)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (120)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (363)
Cancer (2847)
Cardiovascular disease (209)
Career advice (1681)
Career pathing (30)
CAR-T (183)
CDC (30)
Cell therapy (494)
Cervical cancer (22)
Clinical research (66825)
Collaboration (1011)
Company closure (3)
Compensation (680)
Complete response letters (21)
COVID-19 (2624)
CRISPR (56)
C-suite (321)
Cystic fibrosis (111)
Data (2972)
Decentralized trials (2)
Denatured (20)
Depression (58)
Diabetes (346)
Diagnostics (6421)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (135)
Drug pricing (120)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87436)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113717)
Executive appointments (845)
FDA (17884)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (925)
Gene editing (129)
Generative AI (22)
Gene therapy (371)
GLP-1 (777)
Government (4499)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2795)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (491)
Leadership (18)
Legal (7929)
Liver cancer (79)
Lung cancer (399)
Lymphoma (207)
Machine learning (11)
Management (58)
Manufacturing (380)
MASH (90)
Medical device (13456)
Medtech (13461)
Mergers & acquisitions (19574)
Metabolic disorders (844)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (31)
Neuroscience (2107)
NextGen: Class of 2025 (6516)
Non-profit (4488)
Now hiring (47)
Obesity (424)
Opinion (217)
Ovarian cancer (100)
Pain (104)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (295)
Patient recruitment (160)
Peanut (50)
People (57676)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20826)
Phase II (29437)
Phase III (21902)
Pipeline (1618)
Policy (197)
Postmarket research (2563)
Preclinical (8864)
Press Release (64)
Prostate cancer (139)
Psychedelics (35)
Radiopharmaceuticals (253)
Rare diseases (454)
Real estate (5917)
Recruiting (66)
Regulatory (22615)
Reports (50)
Research institute (2324)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (155)
Series B (106)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (75)
Tariffs (57)
The Weekly (36)
Vaccines (777)
Venture capital (53)
Weight loss (254)
Women's health (45)
Worklife (16)
Date
Last 7 days (365)
Last 30 days (1764)
Last 365 days (31173)
2025 (16612)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38197)
Australia (6232)
California (7400)
Canada (2349)
China (668)
Colorado (320)
Connecticut (316)
Delaware (192)
Europe (82085)
Florida (1114)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (360)
Iowa (16)
Japan (226)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5501)
Michigan (245)
Minnesota (448)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2066)
New Mexico (28)
New York (2081)
North Carolina (1076)
North Dakota (8)
Northern California (3258)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1608)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2763)
Tennessee (125)
Texas (1114)
United States (27446)
Utah (219)
Virginia (182)
Washington D.C. (72)
Washington State (629)
West Virginia (4)
Wisconsin (65)
704,715 Results for "nephrosant inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
NephroSant Launches Two-Year Study of 2,000 Kidney Transplant Recipients
NephroSant™, Inc. a biotechnology company dedicated to accelerating the assessment of early kidney damage with a mission to significantly improve global kidney health, announced the first patient has been enrolled into the Assessment of QSant™ for Underlying Allograft Rejection study.
March 21, 2022
·
4 min read
Biotech Bay
NephroSant Features QSant, the first urine test for kidney transplant rejection, at Biotech Showcase Digital 2022
NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that it will present a company overview at the upcoming Biotech Showcase conference.
January 3, 2022
·
4 min read
Biotech Bay
NephroSant Executives Recognized for Contributions to Transplant Care and Advocacy by Prestigious Industry Groups
Dr. Minnie Sarwal, NephroSant Founder, selected as winner of Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation NephroSant Head of Marketing Maria Lopes honored with the Maciak Award at the 2020 Transplant Games of America.
August 16, 2021
·
3 min read
Biotech Bay
NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Rejection Events with QSant
NephroSant™ announced that the Journal of Clinical Medicine has published real-world data (RWD) that provides insight into how changes in allograft health are reflected in specific ranges of QSant™ scores.
March 3, 2022
·
4 min read
Press Releases
CoRegen, Inc. Closes More Than $93 Million Financing
July 10, 2025
·
3 min read
Press Releases
CorMedix inc. Announces Customer Implementation
June 23, 2025
·
3 min read
Press Releases
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
July 7, 2025
·
4 min read
Press Releases
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
July 3, 2025
·
7 min read
Press Releases
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2025
·
3 min read
Press Releases
Verasonics Announces Partnership With PhotoSound Technologies, Inc.
June 24, 2025
·
3 min read
1 of 70,472
Next
